- Trial phase
- Approved (select countries)
- Time to market
- Already approved in select countries (UK, Brazil, Israel, Russia, and others) since 2014; never approved in the US; EU authorization not renewed as of March 2025.
- Why 3/10
- Translarna has no hard, dated binary catalyst in the next 12 months: the US NDA was withdrawn in February 2026, the EU authorization was not renewed in March 2025, and no pivotal readout or PDUFA is scheduled. The drug is an approved but declining commercial product, so impactScore is capped at 3-5 per the rubric.
Translarna has no upcoming regulatory catalysts: the US NDA was withdrawn in February 2026 and the EU conditional authorization was not renewed in March 2025. The drug's revenue is declining ($48.5M in Q3 2026, down from $50.7M a year earlier) and PTC Therapeutics has pivoted to Sephience as its primary growth driver. Watch for further erosion of Translarna's international approvals and whether any individual EU countries maintain access via national provisions.
Price Chart
Executive Summary
Translarna (ataluren) is PTC Therapeutics' oral drug for nonsense mutation Duchenne muscular dystrophy, designed to enable readthrough of premature stop codons. After a decade-long struggle for US approval, PTC withdrew its NDA resubmission in February 2026 following FDA feedback that the data were unlikely to meet the substantial-evidence standard. The EU conditional marketing authorization was not renewed in March 2025 after the EMA concluded effectiveness had not been established. The drug remains approved in the UK, Brazil, Israel, Russia, and a few other markets, generating $48.5M in Q3 2026 revenue (down 4% year-over-year). However, PTC Therapeutics has pivoted sharply: its primary growth driver is now Sephience (sepiapterin) for PKU, which generated $182M in Q3 2026, and the company recently acquired ST-920, a Fabry gene therapy. Translarna is a declining asset with no remaining US or EU regulatory path and no upcoming binary catalysts.
How It Works
Translarna is a small-molecule drug designed to treat Duchenne muscular dystrophy caused by a specific type of genetic error called a nonsense mutation. In patients with this mutation, the body's protein-building machinery stops too early, producing a shortened, non-functional protein. Translarna helps the cellular machinery 'read through' that premature stop signal, allowing production of a full-length, functional protein. It is taken orally as a granule suspension.
Trial Status
Translarna received conditional EU approval in 2014 based on Phase 2/3 data. A confirmatory Phase 3 trial (NCT01247207) was terminated in February 2026. A long-term outcomes Phase 3 study (NCT03179631) completed in 2023. The US NDA resubmission was withdrawn in February 2026 after FDA feedback that the data were unlikely to meet the substantial-evidence standard for approval.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalysts: the US NDA has been withdrawn and the EU authorization was not renewed. Watch for potential individual EU country-level access decisions under national provisions, and further erosion of international approvals.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PTC THERAPEUTICS, INC. 8-K PTCT ·Originating report